Bin Zhang

Dr. Bin Zhang


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2024 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Open access
LGLina Geng
Lina Geng
KPKai Pan
Kai Pan
YXYuhuan Xu
Yuhuan Xu
BZBizhu Zhang
Bizhu Zhang
JWJing Wang
Jing Wang
BZBin Zhang
Bin Zhang
Background: Immunity play a pivotal role in the risk of ischemic stroke, and studies have also shown a relationship between ischemic stroke and autoimmune diseases. In light of this we conducted a prospective cohort study to elucidate the impact of antiphospholipid antibodies (aPLs), antinuclear antibodies (ANA), and antiextractable nuclear antigen autoantibodies (anti-ENA) on the prognosis of ischemic stroke. Methods: 245 stroke patients were recruited in this single-center study and followed up with for 3 years. Autoantibodies, including aPLs (ACA, anti-(32GPI, LA), ANA and anti-ENA were evaluated in recurrent ischemic stroke (RIS) and nonrecurrent ischemic stroke (nonRIS). Stroke severity was judged using the National Institutes of Health Stroke Scale (NIHSS). For preventive treatment, 42 IS patients with positive aPLs + ANA/anti-ENA were randomized 1:1 into a hydroxychloroquine (HCQ) treatment group and a control group, and the prognoses were compared. Results: The positive rate of ACA IgG (p = 0.018), anti-(32GPI IgG (p = 0.047), LA (p = 0.023), and aPLs + ANA/ anti-ENA (p = 0.000) were significantly higher in patients with RIS compared to patients with nonRIS, and aPLs + ANA/anti-ENA (HR2.31, 95 % CI1.02-5.25, p = 0.046) and hypertension (HR2.50, 95 % CI1.17-5.35, p = 0.018) were the independent risk factors of recurrence. There were differences in NIHSS at month 36 between those positive and negative for aPLs + ANA/anti-ENA (p = 0.001, Eta2 = 0.052), anti-ENA (p = 0.016, Eta2 = 0.030), ANA (p = 0.035, Eta2 = 0.022), and LA (p = 0.016, Eta2 = 0.028). Furthermore, the recurrence rate of the HCQ treatment group was lower than that of the control group (p = 0.024). Conclusions: Co-positivity of aPLs and ANA/anti-ENA is an independent risk factor for RIS. However, HCQ therapy may reduce the recurrence rate of IS for these patients.

19 April 2024 in Medicine
Verified
Journal Article
Open access
LGLina Geng
Lina Geng
QCQiang Cuixin
Qiang Cuixin
ZXZhang Xia
Zhang Xia
YJYang Jing
Yang Jing
LZLi Zhirong
Li Zhirong
JZJianhong Zhao
Jianhong Zhao
An increase in CD4+ T cells in the synovium is closely linked to the pathogenesis of rheumatoid arthritis (RA). We aimed to identify the possible causes of the elevated CD4+ T cell levels and to explore the factors influencing disease activity in RA. Fifty-five RA patients, including 28 with active RA (ARA), 27 with inactive RA, and 22 healthy controls, were recruited for this study. The proportion of CCR9+CD4+ T cells and the expression of chemokine receptor 9 (CCR9) on CD4+ T cells were analyzed by flow cytometry. Enzyme-linked immunosorbent assay and chemiluminescent immunoassay were used to evaluate interleukin (IL)-17A and IL-6 levels, respectively. The proportion of CCR9+CD4+ T cells and the expression of CCR9 on CD4+ T cells increased significantly in peripheral blood (PB) and synovial fluid (SF) in ARA compared to those in inactive RA. Furthermore, SF contained more CCR9+CD4+ T cells, IL-6, and IL-17A than PB in RA patients. Moreover, CD4+ T cells in the PB of patients with RA, especially ARA, expressed more CCR9 and secreted more IL-6 and IL-17A after activation. Here, we also demonstrated that both the percentage of CCR9+ cells in CD4+ T cells and the expression of CCR9 on circulating CD4+ T cells were positively correlated with erythrocyte sedimentation rate, hypersensitive C-reactive protein, rheumatoid factor, and anti-cyclic citrullinated peptide antibody. CCR9+CD4+ T cells are elevated in PB and SF, and are associated with disease activity in patients with RA.

27 March 2025 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
LGLina Geng
Lina Geng
TLTing Li
Ting Li
YLYan Liu
Yan Liu
XLXuntao Liu
Xuntao Liu
JWJing Wang
Jing Wang
BZBin Zhang
Bin Zhang

22 November 2024 in Medicine
Verified
Journal Article
Open access
XCXinran Mm Cao
Xinran Mm Cao
DGDiyuan Mm Guo
Diyuan Mm Guo
BZBin Zhang
Bin Zhang
This study analyzes the laboratory characteristics and prognosis of patients between PML-RARα negative APL and PML-RARα positive APL and compares the differences in order to improve the understanding of this rare APL and guide clinical diagnosis and treatment. A total of 81 patients with newly diagnosed APL based on bone marrow cell morphology were included, with 14 in the PML-RARα gene negative group and 67 in the PML-RARα gene positive group. The sex, age, peripheral blood routine test, coagulation related indicators, bone marrow cell morphology, flow cytometric immunophenotype, abnormal chromosome expression and prognosis of the 2 groups were analyzed and compared. PML-RARα gene-negative and PML-RARα gene-positive groups were statistically significant in leukocyte count, fibrinogen content, proportion of abnormal promyelocytes, positive rate of Auer bodies, strongly positive peroxidase staining, positive CD13, CD4, CD11b, CD15, CD25 expression and complete response rate during 1 course (P < .05). By the end of follow-up in February 2021, the duration of CR in the PML-RARα gene-negative group was short (P < .05). This study found that the efficacy and prognosis of patients with PML-RARα gene negative were worse than those of the positive group, but the correlation between indicators and prognosis needs to be further explored and confirmed in more diverse samples.

14 January 2026 in Clinical Rheumatology
Verified
Journal Article
Closed access
PDF file
XWXia Wang
Xia Wang
YZYe Zhang
Ye Zhang
SZSutao Zhou
Sutao Zhou
XLXuntao Liu
Xuntao Liu
BZBin Zhang
Bin Zhang
BZBo Zhang
Bo Zhang

10 April 2026 in Medicine
Verified
Journal Article
Open access
XWXia Mm Wang
Xia Mm Wang
YZYe Mm Zhang
Ye Mm Zhang
XLXuntao Mm Liu
Xuntao Mm Liu
SZSutao Mm Zhou
Sutao Mm Zhou
PCPeng Mbbs Cheng
Peng Mbbs Cheng
BZBin Zhang
Bin Zhang
Evidence regarding the association between serum Klotho levels and thrombocytopenia remains limited. This study aimed to evaluate the relationship between serum Klotho and thrombocytopenia. This study used data from the National Health and Nutrition Examination Survey conducted between 2007 and 2016 to investigate the association between serum Klotho levels and thrombocytopenia in middle-aged and older individuals. Weighted multivariable logistic regression, interaction subgroup analysis, restricted cubic splines and threshold effect analysis were used to examine the correlation between serum Klotho levels and thrombocytopenia. The study included 13,716 individuals, among whom thrombocytopenia was present in 4.5% of the participants. The multivariate adjusted odds ratio (OR) (95% CI) for T2 to T3 was 1.19 (0.86–1.63) and 1.50 (1.12–2.01), respectively. The risk of developing thrombocytopenia was significantly higher in the T3 group compared to T1 ( P = .007). Smooth curve fitting revealed a nonlinear association between serum Klotho and thrombocytopenia ( P < .001), with an inflection point at 900 pg/mL. Individuals with higher serum Klotho levels were significantly associated with increased odds of thrombocytopenia, particularly among those with serum Klotho concentrations ≥ 900 pg/mL (per SD increment: OR, 1.24; 95% CI: 1.08–1.43). We observed that higher serum Klotho levels (≥900 pg/mL) were significantly associated with the presence of thrombocytopenia in the general population. Given the cross-sectional design of the study, causality cannot be inferred. The elevated Klotho levels may reflect a compensatory response, and further longitudinal and mechanistic studies are needed to clarify the underlying biological mechanisms.